Company profile: Oxyrane
1.1 - Company Overview
Company description
- Provider of novel and biosuperior enzyme replacement therapies for lysosomal storage diseases. Pipeline includes OxyGCase for neuronopathic Gaucher disease and OXY2810 for Pompe disease. Offers the OxyCAT glycoengineered yeast-based platform to produce ERTs with enhanced cellular uptake and pharmacodynamics.
Products and services
- OxyCAT Platform: Proprietary glycoengineered yeast-based system that produces enzyme replacement therapies with enhanced cellular uptake and pharmacodynamics, supporting development of biosuperior ERTs for lysosomal storage diseases
- OxyGCase: In-development enzyme replacement therapy for neuronopathic Gaucher disease, engineered to enhance uptake by neuronal cells to facilitate improved delivery and internalization within target neuronal cell populations
- OXY2810: Recombinant human enzyme for enzyme replacement therapy in Pompe disease, aimed at restoring lysosomal acid alpha glucosidase activity, focusing on reconstituting essential enzyme function within lysosomes
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Oxyrane
Cosciens Bio
HQ: United States
Website
- Description: Provider of biopharmaceutical diagnostic products, including Macimorelin, an orally active small molecule to diagnose adult growth hormone deficiency (AGHD), approved by the U.S. FDA and European Commission, and Macimorelin for childhood-onset growth hormone deficiency (CGHD) under development, leveraging its safety profile and clinical success in AGHD.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cosciens Bio company profile →
Forge Biologics
HQ: United States
Website
- Description: Provider of end-to-end AAV gene therapy manufacturing and development services from preclinical to commercial stages, including plasmid DNA production (research-grade to cGMP), turnkey research-grade AAV via Blaze Vector Production using proprietary Ignition Cells, process and analytical development, cGMP production in 50L to 5,000L bioreactors, integrated regulatory solutions, and a 200,000+ sq. ft. cGMP facility.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Forge Biologics company profile →
Primrose Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology research and development focused on creating treatments for polycystic kidney disease (PKD), a life-threatening genetic disorder affecting 600,000 Americans and 12.5 million people worldwide.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Primrose Therapeutics company profile →
Dynacure
HQ: France
Website
- Description: Provider of clinical-stage drug development focused on rare and orphan diseases, building a pipeline of novel antisense therapies. Offerings include DYN101, an investigational antisense medicine; danvatirsen (STAT3), in Phase 2 for HNSCC and Phase 1 for AML/MDS; FTX-001 (MALAT1), ready for clinical trials; and PEMDA-HN, a study of danvatirsen with pembrolizumab for recurrent/metastatic HNSCC.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dynacure company profile →
Kedrion Biopharma
HQ: United States
Website
- Description: Provider of plasma-derived therapies and services, including RYPLAZIM (human plasminogen) for plasminogen deficiency type 1, Yimmugo (intravenous immunoglobulin G) for primary humoral deficiency in patients aged 2 years and older, plasma collection to produce plasma-derived medicinal products, and pharmacovigilance activities to detect, assess, understand, and prevent adverse effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kedrion Biopharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Oxyrane
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Oxyrane
2.2 - Growth funds investing in similar companies to Oxyrane
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Oxyrane
4.2 - Public trading comparable groups for Oxyrane
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →